Medytox, a R&D-based global biopharmaceutical company, engages in the development, manufacture, marketing and sales of botulinum toxin products and hyaluronic acid dermal filler products as its main business. Since the successful development of the fourth botulinum toxin type A product in the world, Medytox has built world-class R&D infrastructure and highly capable expert teams for the best biotechnology. Medytox has also received global recognition for its unparalleled technology by signing the largest license agreement ever in Korean pharmaceutical industry with the global pharmaceutical company, Allergan Inc. Today, Medytox is exporting its products to about 60 countries including Japan, Thailand, India and Brazil. Moreover, Medytox has been making efforts to penetrate into the US and European market in the near future. Ultimately, Medytox is going to show its presence as a leading global biopharmaceutical company.